The resurgence of platinum-based cancer chemotherapy

By L. Kelland. Nature Reviews. Cancer, 2007

4,374 citations recorded by the source corpus.

Subfields: Hematology, Oncology

View Paper: https://www.semanticscholar.org/paper/f589dd5ca77e324b57154ffb843cf9857e94d33e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. A. D’Andrea
2. Raphael Ceccaldi
3. S. Mitragotri
4. A. Anselmo

In Oncology

1. Guido Kroemer
2. L. Galluzzi
3. L. Zitvogel
4. Oliver Kepp
5. N. Nagarsheth
6. A. Tesnière
7. A. D’Andrea
8. W. Zou

Citations in the corpus

• High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs (2008, background): “Because PARP1 might be involved in both base-excision repair (BER) and NER (26), synergy between PARP inhibitors and platinum drugs could be anticipated.”
• Molecular mechanisms of cisplatin resistance (2012, background): “The cytotoxicity of cisplatin (which is given intravenously as short-term infusion in physiological saline) also affects kidneys (nephrotoxicity), peripheral nerves (neurotoxicity) and the inner ear (ototoxicity) (Cvitkovic et al., 1977; Kelland, 2007).”
• Cisplatin in cancer therapy: molecular mechanisms of action (2014, neutral): “It was the first FDA-approved platinum compound for cancer treatment in 1978 (Kelland, 2007).”
• Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer (2015, background): “ICLs are extremely deleterious lesions that covalently tether both duplex DNA strands and pose formidable blocks to DNA repair (13).”
• Mechanisms of DNA damage, repair and mutagenesis (2017, neutral): “3B), the first FDA approved platinum compound that is used to treat a wide variety of cancers [Kelland, 2007; Dasari and Tchounwou, 2014].”
• Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. (2012, neutral): “Identification of nonresponders and patients with primary platinum resistance (recurrence less than 6 months after last chemotherapy cycle) is an important step toward achieving greater life expectancy for serous ovarian carcinoma patients (7).”
• Immunogenic death of colon cancer cells treated with oxaliplatin (2010, methodology): “This difference in the ability to trigger immunogenic cell death may be one plausible explanation to understand the lack of efficacy of CDDP in CRC patients.”
• Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy (2017, background): “Oxaliplatin, another chemotherapy drug, inhibits tumor cell growth and causes cell G2 phase arrest by covalently binding DNA and forming platinum-DNA adducts (Kelland, 2007).”